Screener
BioMarin Pharmaceuticals BMRN Interest expense on dilutive Convertible Notes
Interest expense on dilutive Convertible Notes at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestOnConvertibleDebtNetOfTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
FAQ
- What is BioMarin Pharmaceuticals's interest expense on dilutive convertible notes?
- BioMarin Pharmaceuticals (BMRN) reported interest expense on dilutive convertible notes of $0 in Q2 2026.
- How has BioMarin Pharmaceuticals's interest expense on dilutive convertible notes changed year-over-year?
- BioMarin Pharmaceuticals's interest expense on dilutive convertible notes decreased by 100.0% year-over-year, from $1.83M to $0.
- What does interest expense on dilutive convertible notes mean?
- Interest expense on dilutive Convertible Notes as reported by BioMarin Pharmaceuticals Inc.
Ask your AI about BioMarin Pharmaceuticals's interest expense on dilutive convertible notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude